Posted: Oct 13, 2017 by Jennifer Sipos

ITOG Announces Inaugural Robert F. Gagel Discovery Award

Dr. Robert F. Gagel is a principal founder of ITOG.

Posted: May 3, 2017 by Jennifer Sipos

Long term trends in thyroid cancer incidence and mortality

Investigators from the National Cancer Institute, Division of Cancer Epidemiology and Genetics (DCEG), and Duke University Medical Center evaluated long-term trends in thyroid cancer incidence and mortality according to histology, stage, and tumor size at diagnosis.

Posted: Mar 7, 2016 by ITOG Administrator

Update on the interNational Anaplastic Thyroid cancer Tissue bank project (iNATT)

The interNational Anaplastic Thyroid Cancer Tissue Bank and Database project (iNATT) was launched in the UK in 2013 and extended internationally in 2014.

Posted: Dec 18, 2015 by ITOG Administrator

Update on ITOG Selumetinib Trial

Dr. Alan Ho
The selumetinib clinical trial led by Dr. Alan Ho of Memorial Sloan Kettering Cancer Center in New York, NY is now open. The trial evaluates the effectiveness of selumetinib to enhance uptake of radioactive iodine (RAI) for treatment of advanced thyroid cancer. This is a large, multicenter,...

Posted: Dec 18, 2015 by ITOG Administrator

Initial Findings of ITOG's First Clinical Trial

Dr. Manisha H. Shah
Preliminary results of the first clinical trial initiated by ITOG have been evaluated, marking a major accomplishment for ITOG. The goal of this multi-institution clinical trial, led by Dr. Manisha H. Shah from Ohio State University, is to examine whether patients who had progression of their...

Posted: Dec 18, 2015 by ITOG Administrator

ITOG Scientists Outline Important Research Benchmarks

ITOG is dedicated to improving the survival and quality of life among patients with thyroid cancer. As part of that mission, the Correlative Sciences Committee of the ITOG has thoughtfully developed a position statement regarding the need for robust correlative studies in thyroid cancer clinical...

Posted: Oct 26, 2015 by ITOG Administrator

Cabozantinib impact on thyroid tumor shrinkage

Dr. Manisha Shah, ITOG investigator, discusses the impact of cabozantinib on thyroid tumor shrinkage.  Watch the video here: Click here for the video.  

Posted: Jun 29, 2015 by Yariv Houvras

Clinical trial of a very well tolerated drug for an uncommon form of thyroid cancer

The drug Pioglitazone (Actos) is being used in a clinical trial for thyroid cancers that contain a specific mutation called PAX8-PPARgamma. PAX8-PPARgamma is uncommon, but is found in some thyroid cancers of the following types: follicular; follicular variant of papillary; and poorly...

Posted: May 15, 2015 by ITOG Administrator

Molecular characterization of thyroid cancers reported at ITOG Annual Meeting

Thomas Giordano
The 2015 ITOG International Meeting was recently held in Rome, Italy, where Dr. Thomas Giordano presented the lead talk on a new comprehensive analysis of thyroid cancer from The Cancer Genome Atlas (TCGA) Research Network, a federally funded project to elucidate the molecular characterization of...

Posted: Feb 12, 2015 by ITOG Administrator

FDA Approves Lenvima for Thyroid Cancer based on SELECT results

A large, multi-center phase 3 study (SELECT trial) has found that patients with progressive, iodine refractory differentiated thyroid cancer have markedly improved progression free survival (PFS) when treated with lenvatinib, an oral tyrosine kinase inhibitor. Multiple ITOG members participated in...



International Thyroid Oncology Group
5166 Commercial Drive
Yorkville, New York 13495